within Pharmacolibrary.Drugs.ATC.J;

model J05AF03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.83,
    Cl             = 0.004083333333333333,
    adminDuration  = 600,
    adminMass      = 0.75 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00074,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0235,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AF03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Zalcitabine is a nucleoside reverse transcriptase inhibitor (NRTI) formerly used in the treatment of HIV infection. It inhibits viral replication by interfering with reverse transcriptase activity. Due to toxicity concerns and the development of better alternatives, zalcitabine has been withdrawn from the market and is not currently approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following oral administration in HIV-infected adult patients; typically studied population included males and females aged 18-60 with normal renal and hepatic function.</p><h4>References</h4><ol><li><p>Jung, D, et al., &amp; Griffy, K (1999). The pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients. <i>Journal of clinical pharmacology</i> 39(5) 505–512. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10234599/&quot;>https://pubmed.ncbi.nlm.nih.gov/10234599</a></p></li><li><p>Foster, RH, &amp; Faulds, D (1998). Abacavir. <i>Drugs</i> 55(5) 729–738. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199855050-00018&quot;>10.2165/00003495-199855050-00018</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9585869/&quot;>https://pubmed.ncbi.nlm.nih.gov/9585869</a></p></li><li><p>Lea, AP, &amp; Faulds, D (1996). Ritonavir. <i>Drugs</i> 52(4) 541–548. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199652040-00007&quot;>10.2165/00003495-199652040-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8891466/&quot;>https://pubmed.ncbi.nlm.nih.gov/8891466</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AF03;
